[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatic-steatosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatic-steatosis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,64,88,116],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100577705","study-for-the-identification-of-a-score-to-assess-intrapancreatic-fat-through-eco-elastography-and-its-correlation-with-metabolic-syndrome-and-insulin-secreting-cells-100577705",false,"NCT06801769","Study for the Identification of a Score to Assess Intrapancreatic Fat Through Eco-Elastography and Its Correlation With Metabolic Syndrome and Insulin-Secreting Cells.","Study for the Identification of a Quantitative Eco-Elastographic Score of Pancreatic Steatosis and Its Correlation With Beta-Cell Function and Metabolic Syndrome.","SPES","Inclusion Criteria:\n\n* Age between 18 and 80 years\n* HbA1c \\\u003C10% or fasting glucose \\\u003C250 mg\u002FdL\n* Ability to understand and provide informed consent regarding the procedures, data collection, and analysis.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years or \\>80 years\n* History of diabetes treated with insulin\n* HbA1c \\>10% or fasting glucose \\>250 mg\u002FdL\n* Pancreatic diseases (solid tumors\u002Fsecretory NETs\u002Fcystic fibrosis; non-secretory NETs and IPMN may be included)\n* Previous pancreatic surgery\n* Moderate anemia (Hb \\\u003C10 mg\u002FdL)\n* Severe liver failure (Child-Pugh C)\n* Non-metabolic causes of NAPLD (e.g., corticosteroid therapy, antiretrovirals, gemcitabine, octreotide, history of hemochromatosis, malnutrition, HBV\u002FHIV infections)\n* Alcohol abuse (\\>30 g\u002Fday of ethanol)\n* Pregnancy and breastfeeding\n* Inability to adequately understand informed consent and study procedures","ALL","18 Years","80 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"NA","\\*\\*Brief Summary of the SPES Clinical Study\\*\\*\n\nThe SPES clinical study aims to evaluate the relationship between pancreatic fat accumulation (pancreatic steatosis) and metabolic health. Pancreatic steatosis has been linked to conditions like type 2 diabetes (T2D) and metabolic syndrome, but the underlying mechanisms and its impact on beta-cell function remain poorly understood.\n\nThe primary goal of this study is to develop a quantitative ultrasound elastography score to measure the degree of pancreatic steatosis and explore how this relates to pancreatic beta-cell function and key factors associated with the development of type 2 diabetes and metabolic syndrome.\n\nA secondary goal is to categorize participants into four risk classes for type 2 diabetes based on their metabolic profiles and correlate these classes with the degree of pancreatic steatosis. This may provide insights into individual risk stratification for T2D and related complications.\n\nThe study will enroll 100 participants, aged 18 to 80, attending the Endoscopic Ultrasound Unit at the Fondazione Policlinico Universitario Agostino Gemelli in Rome. Participants will undergo endoscopic ultrasound for various clinical reasons, excluding those with pancreatic tumors, cystic fibrosis, or insulin-treated diabetes. Key inclusion criteria include controlled blood glucose levels (HbA1c \\\u003C 10% or fasting glucose \\\u003C 250 mg\u002FdL) and the ability to understand and provide informed consent.\n\nThe study is interventional but does not involve drugs or medical devices. Participants will attend a visit where medical history, physical measurements (e.g., BMI, waist circumference, blood pressure), glucose tolerance tests, and blood work will be collected. This comprehensive approach aims to better understand the metabolic implications of pancreatic steatosis and its role in type 2 diabetes development.\n\nThe study will last 24 months, including the enrollment period. Findings may contribute to improved risk stratification, prevention, and management strategies for type 2 diabetes and related conditions.",[28,29,30],"Pancreatic Steatosis","Metabolic Syndrome X","Diabetes Mellitus","RECRUITING","2026-03-18",{"date":34,"type":35},"2026-03-20","ACTUAL",{"date":37,"type":35},"2025-03-17",{"date":39,"type":22},"2026-12",{"name":41,"class":42},"Catholic University of the Sacred Heart","OTHER",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":14,"acronym":15,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":61,"locationsCount":63},"100604896","identification-of-a-score-for-the-assessment-of-intrapancreatic-fat-100604896","NCT07155473","Identification of a Score for the Assessment of Intrapancreatic Fat","Exclusion Criteria\n\n* Age \\\u003C18 years or \\>80 years\n* History of diabetes treated with insulin\n* HbA1c \\>10% or fasting glucose \\>250 mg\u002FdL\n* Pancreatic diseases (solid tumors\u002Fsecretory NETs\u002Fcystic fibrosis; non-secretory NETs and IPMN may be included)\n* Previous pancreatic surgery\n* Moderate anemia (Hb \\\u003C10 mg\u002FdL)\n* Severe liver failure (Child-Pugh C)\n* Non-metabolic causes of NAPLD (e.g., corticosteroid therapy, antiretrovirals, gemcitabine, octreotide, history of hemochromatosis, malnutrition, HBV\u002FHIV infections)\n* Alcohol abuse (\\>30 g\u002Fday of ethanol)\n* Pregnancy and breastfeeding\n* Inability to adequately understand informed consent and study procedures\n\nInclusion Criteria:\n\n* Age between 18 and 80 years\n* HbA1c \\\u003C10% or fasting glucose \\\u003C250 mg\u002FdL\n* Ability to understand and provide informed consent regarding the procedures, data collection, and analysis.",{"count":21,"type":22},[25],"The SPES clinical study aims to evaluate the relationship between pancreatic fat accumulation (pancreatic steatosis) and metabolic health. Pancreatic steatosis has been linked to conditions like type 2 diabetes (T2D) and metabolic syndrome, but the underlying mechanisms and its impact on beta-cell function remain poorly understood.\n\nThe primary goal of this study is to develop a quantitative ultrasound elastography score to measure the degree of pancreatic steatosis and explore how this relates to pancreatic beta-cell function and key factors associated with the development of type 2 diabetes and metabolic syndrome.\n\nA secondary goal is to categorize participants into four risk classes for type 2 diabetes based on their metabolic profiles and correlate these classes with the degree of pancreatic steatosis. This may provide insights into individual risk stratification for T2D and related complications.\n\nThe study will enroll 100 participants, aged 18 to 80, attending the Endoscopic Ultrasound Unit at the Fondazione Policlinico Universitario Agostino Gemelli in Rome. Participants will undergo endoscopic ultrasound for various clinical reasons, excluding those with pancreatic tumors, cystic fibrosis, or insulin-treated diabetes. Key inclusion criteria include controlled blood glucose levels (HbA1c \\\u003C 10% or fasting glucose \\\u003C 250 mg\u002FdL) and the ability to understand and provide informed consent.\n\nThe study is interventional but does not involve drugs or medical devices. Participants will attend a visit where medical history, physical measurements (e.g., BMI, waist circumference, blood pressure), glucose tolerance tests, and blood work will be collected. This comprehensive approach aims to better understand the metabolic implications of pancreatic steatosis and its role in type 2 diabetes development.\n\nThe study will last 24 months, including the enrollment period. Findings may contribute to improved risk stratification, prevention, and management strategies for type 2 diabetes and related conditions.",[28,29,54],"Diabetes","2025-08-27",{"date":57,"type":35},"2025-09-04",{"date":59,"type":35},"2025-03-01",{"date":39,"type":22},{"name":62,"class":42},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",1,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":72,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":23,"phases":75,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":63},"100464987","determination-of-pancreatic-steatosis-prevalence-and-correlation-with-high-risk-cyst-features-100464987","NCT05334836","Determination of Pancreatic Steatosis Prevalence and Correlation With High-risk Cyst Features","Determination of Pancreatic Steatosis Prevalence and Correlation With High-risk Cyst Features in Patients With Pre-malignant Pancreatic Cystic Neoplasms Using Magnetic Resonance Imaging and Endoscopic Ultrasound","FPPCN","Inclusion Criteria:\n\n1. Age 18 or older\n2. Patients with at least 1 pancreatic cystic lesion presumed to be IPMN or MCN based on CT, MRI or EUS features, with a cyst size ≥ 5mm; or healthy subjects.\n3. Patients who are able to provide written informed consent to participate in the study and comply with the study procedures.\n\nExclusion Criteria:\n\n1. Unable to provide written informed consent\n2. Patients with metallic implants or other contraindications to MRI\n3. Patients with contraindications for endoscopy due to comorbidities\n4. Patients with known pancreatic cancer or prior pancreatic resection\n5. Patients with significant alcohol consumption, defined as alcohol intake of over 20 g daily (140 g weekly) for men and 10 g daily (70 g weekly) for women",true,{"count":74,"type":22},236,[25],"Pancreatic cancer is the fifth leading cause of cancer mortality in Hong Kong and the seventh leading cause of cancer mortality worldwide. In 2020, approximately 496000 new cases of pancreatic cancers were diagnosed globally . Pancreatic cancer is a highly fatal cancer with a case-fatality rate of 94.0% globally. In Hong Kong, both the incidence and mortality of pancreatic cancer have increased over the past decade.\n\nDue to the deep-seated location of pancreas, it is difficult to diagnose pancreatic cancer at an early stage, which in turn leads to delays in cancer treatment and poorer survival. Despite advances in oncologic treatment, the 5-year survival rate of metastatic pancreatic cancer remains poor (\\~2.9%). As such, there has been growing interest to improve pancreatic cancer prevention and survival by:\n\n1. reduction of modifiable risk factors (eg, cigarette smoking, obesity, diabetes),\n2. screening for early detection of high-risk pre-malignant lesions in selected high-risks patients with strong family history of pancreatic cancer and\u002For certain germline mutations of pancreatic cancer susceptibility genes (eg, BRCA1, BRAC2, DNA mismatch repair genes in Lynch Syndrome, etc) by magnetic resonance imaging (MRI) or endoscopic ultrasound (EUS), and\n3. surveillance of pre-malignant precursor lesions such as mucinous pancreatic cystic neoplasms (PCN) by imaging and\u002For EUS to identify high-risk neoplastic progression indicated for surgical resection.",[28,78],"Pancreatic Cyst","2025-08-06",{"date":81,"type":35},"2025-08-11",{"date":83,"type":35},"2022-04-06",{"date":85,"type":22},"2026-04-30",{"name":87,"class":42},"Chinese University of Hong Kong",{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":98,"phases":4,"briefSummary":99,"conditions":100,"keywords":103,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":63},"100574289","fatty-liver-and-pancreatic-steatosis-100574289","NCT06757348","Fatty Liver and Pancreatic Steatosis","Association Between Fatty Liver and Pancreatic Steatosis in Patients With Metabolic Syndrome","Inclusion Criteria:\n\n* Patients over 18 years old with a diagnosis of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).\n\nExclusion Criteria:\n\n* \\- Alcohol consumption \\>20 g\u002Fday in women, \\>30 g\u002Fday in men\n* Chronic hepatitis B or C infection\n* Autoimmune liver diseases: autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis\n* Hereditary hemochromatosis\n* Wilson's disease\n* Alpha-1 antitrypsin deficiency\n* Celiac disease\n* Uncontrolled thyroid disease\n* Active or chronic infectious disease\n* Active cancer or ongoing treatment\n* Chronic renal insufficiency\n* Pregnancy\u002Flactation\n* Insufficient data\n* Patients who do not complete follow-up","65 Years",{"count":97,"type":22},61,"OBSERVATIONAL","The goal of this observational study is to determine the prevalence of pancreatic steatosis in patients with fatty liver and determine the prevalence of exocrine pancreatic insufficiency (EPI) in these patients.\n\nParticipants with fatty liver and metabolic syndrome will undergo fecal elastase measurement and endoscopic ultrasound (EUS).",[101,102,28],"Exocrine Pancreatic Insufficiency","Fatty Liver, Nonalcoholic",[104,105,106],"Fatty liver","Pancreatic steatosis","Metabolic syndrome","NOT_YET_RECRUITING","2025-08-05",{"date":79,"type":35},{"date":111,"type":22},"2025-09-01",{"date":113,"type":22},"2026-03-01",{"name":115,"class":42},"Maria Marta Piskorz",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":72,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":98,"phases":4,"briefSummary":126,"conditions":127,"keywords":129,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":63},"100582735","prevalence-of-pancreatic-steatosis-in-pancreatic-cystic-neoplasms-and-pancreatic-adenocarcinoma-100582735","NCT06867172","Prevalence of Pancreatic Steatosis in Pancreatic Cystic Neoplasms and Pancreatic Adenocarcinoma","The Emerging Issue - Pancreatic Steatosis Prevalence in Pancreatic Cystic Neoplasms and Adenocarcinoma: Insights From a Single-center Retrospective Study","SPACE","Inclusion Criteria:\n\n* Age 18 or older\n* Patients with at least 1 pancreatic cystic lesion based on CT and EUS features, with a cyst size ≥ 5mm; or healthy subjects or PDAC (confirmed by histopathological exam).\n\nExclusion Criteria:\n\n* No evidence of written informed consent\n* Patients with contraindications for endoscopy due to comorbidities\n* Metal stent in hepato-bilio-pancreatic region at time of baseline CT-imaging (vascular, luminal and biliary)\n* Acute pancreatitis at baseline imaging\n* Pancreatic surgery at baseline imaging in our department\n* Splenectomy\n* Patients with significant alcohol consumption, defined as alcohol intake of over 20 g daily (140 g weekly) for men and 10 g daily (70 g weekly) for women",{"count":125,"type":22},66,"Several pancreatic neoplastic cystic lesions, such as IPMN (intrapapilary mucinous neoplasia), cystic neuroendocrine tumors (NET) and mucinous neoplasms, present a carcinogenetic risk, though it is yet unknown if this risk is increased in patients with pancreatic steatosis (PS).\n\nThe primary objective of the study is to determine de prevalence of pancreatic steatosis in pancreatic neoplastic cysts and if pancreatic steatosis is increased in those lesions that pose a carcinogenetic risk.\n\nThe secondary objective is to evaluate the prevalence of pancreatic steatosis in pancreatic adenocarcinoma.",[28,78,128],"Pancreatic Adenocarcinoma",[130,131,132,133,134,135],"pancreas","steatosis","cyst","cancer","adenocarcinoma","fat","2025-03-06",{"date":138,"type":35},"2025-03-10",{"date":140,"type":35},"2019-01-01",{"date":142,"type":22},"2025-06-30",{"name":144,"class":42},"Carol Davila University of Medicine and Pharmacy"]